Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 11, 2020
December 17, 2024
98000d9a-b1f7-4dbc-8bf5-8079e3a4b3a7
Related Documents
Expedited Programs for Serious Conditions | Drugs and Biologics
Guidance DocumentMay 30, 2014Center for Drug Evaluation and Research
Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers : Guidance for Industry
Guidance DocumentJune 13, 2018Center for Drug Evaluation and Research
Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers: Guidance for Industry and Review Staff
Guidance DocumentJune 13, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.